PMC:7696151 / 78166-78367 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"2290","span":{"begin":16,"end":19},"obj":"Chemical"},{"id":"2291","span":{"begin":69,"end":84},"obj":"Chemical"},{"id":"2294","span":{"begin":119,"end":124},"obj":"Disease"}],"attributes":[{"id":"A2290","pred":"tao:has_database_id","subj":"2290","obj":"MESH:D006886"},{"id":"A2291","pred":"tao:has_database_id","subj":"2291","obj":"MESH:C017092"},{"id":"A2294","pred":"tao:has_database_id","subj":"2294","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ministration of HCQ (60 mg/kg i.p.) and the antiglycolytic inhibitor 3-bromopyruvate possessed a synergistic effect on tumor growth inhibition. Moreover, this treatment is associated with an improvemen"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T171","span":{"begin":119,"end":124},"obj":"Phenotype"}],"attributes":[{"id":"A171","pred":"hp_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"ministration of HCQ (60 mg/kg i.p.) and the antiglycolytic inhibitor 3-bromopyruvate possessed a synergistic effect on tumor growth inhibition. Moreover, this treatment is associated with an improvemen"}